by Nicole Espinoza, Oct 31, 2019
The evolution of risk-shifting between payers, patients, and manufacturers is not completely accounted for in the structuring of rebate contracts. Much of the focus of these negotiations center around relative copay differentials and utilization management restrictions. Often ignored is the fact that, for many drugs, patients seldom pay the negotiated copay amounts. The rise of medical and pharmacy deductibles that total thousands of dollars negate these negotiated copays. These deductibles... Read More
